Upgrade to SI Premium - Free Trial

Amarin Corp. (AMRN)

14.26 +0.03 (0.21%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (10/29/26 *Est.)

Latest Headlines

Amarin Corp. (AMRN) Reports In-Line Q2 EPS July 29, 2026 7:26 AM - StreetInsider Amarin Reports 2026 Second Quarter Financial Results Demonstrating Early Success of Fully Partnered International Commercial Strategy and Continued Leading U.S. Market Presence July 29, 2026 7:00 AM - StreetInsider Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Keenan David Paul July 15, 2026 5:00 PM - SEC Filing Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Ketchum Steven B July 15, 2026 5:00 PM - SEC Filing Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Fishman Peter L. July 15, 2026 5:00 PM - SEC Filing Form 4 AMARIN CORP PLC\UK For: Jul 01 Filed by: Provoost Jonathan July 15, 2026 5:00 PM - SEC Filing Amarin to Report Second Quarter 2026 Financial Results and Host Conference Call on July 29, 2026 July 15, 2026 8:00 AM - StreetInsider Form 4 AMARIN CORP PLC\UK For: Jun 26 Filed by: Berg Aaron June 30, 2026 5:20 PM - SEC Filing Amarin highlights Vascepa cost advantage over new injectable rivals June 30, 2026 4:16 PM - StreetInsider Amarin Reaffirms the Proven, Guideline-Recommended Role of VASCEPA® (Icosapent Ethyl) in an Evolving Triglyceride Treatment Landscape  June 30, 2026 4:15 PM - StreetInsider U.S. Supreme Court rules in favor of generic drugmaker Hikma in 'skinny label' patent dispute over Amarin heart drug vascepa June 4, 2026 10:02 AM - StreetInsider Amarin presents analysis on risk-weighted apoB for cardiovascular patients May 27, 2026 8:01 AM - StreetInsider New REDUCE-IT® Analysis Presented at the European Atherosclerosis Society (EAS) Congress 2026 Suggests Risk-Weighted ApoB May Improve Identification of Residual Cardiovascular Risk in Statin-Treated May 27, 2026 8:00 AM - Globe NewsWire Full Article List